1. EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer 
Sarita Dubey, MD, Patricia Stephenson, ScD, Donna E. Levy, MS, Judith A. Miller, BS, Steven M. Keller, MD, Joan H. Schiller, MD, David H. Johnson, MD, Jill M. Kolesar, PharmD 
Journal of Thoracic Oncology 
Volume 1, Issue 5, Pages (June 2006)
DOI: /S (15)
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1 Intron 1 CA repeat direct sequencing by Chromas version 2.3.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Survival did not correlate with allele status. There was no statistically significant difference between the median survival of homozygous (50.7 months) and heterozygous (38.5 months) alleles (p = 0.40).
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Survival correlated with the number of dinucleotide repeats when dichotomized by mean sum of alleles. Allele sum of less than or equal to 35 had a median overall survival of 29.2 months (95% CI, 21.3–51.4 months), whereas patients with an allele sum greater than 35 had a median overall survival of 41.0 months (95% CI, 35.8–66.3 months; HR, 0.66; p = 0.03).
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions